Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.72 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.72 |
| ▸ | TTR | P02766 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
| ▸ | THPO | P40225 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8222027 | 0.91 | KDM4E (0.68) | LCKALOX12ALOX5TTRCYP3A4 | |
| SCHEMBL1932873 | 0.89 | LCK (0.91) | LCKALOX12ALOX5TTRCYP3A4 | |
| SCHEMBL15026144 | 0.89 | LCK (0.91) | LCKALOX12ALOX5TTRCYP3A4 | |
| SCHEMBL14156517 | 0.86 | ALOX5 (0.56) | LCKALOX12ALOX5TTRCYP3A4 | |
| Piceatannol SCHEMBL19953785 | 0.85 | LCK (1.00) | LCKALOX12ALOX5TTRCYP3A4 | |
| Piceatannol SCHEMBL43541 | 0.85 | LCK (1.00) | LCKALOX12ALOX5TTRCYP3A4 | |
| Piceatannol SCHEMBL29929133 | 0.85 | LCK (1.00) | LCKALOX12ALOX5TTRCYP3A4 | |
| Piceatannol SCHEMBL29501290 | 0.85 | LCK (1.00) | LCKALOX12ALOX5TTRCYP3A4 | |
| Piceatannol SCHEMBL29754702 | 0.85 | LCK (1.00) | LCKALOX12ALOX5TTRCYP3A4 | |
| Piceatannol SCHEMBL505561 | 0.85 | LCK (1.00) | LCKALOX12ALOX5TTRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224637-A1 | INTRANSAL DELIVERY OF CURCUMIN | DePuy Synthes Products, Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160374960-A1 | Method of Topically Administering a Curcumin Derivative | JOHNSON & JOHNSON CONSUMER, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20140163116-A1 | METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE | DePuy Synthes Products, LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130150628-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE | DIMAURO THOMAS M (US) | 2013-06-13 | — | — | US | disclosed |
| US-8383865-B2 | Curcumin derivatives | CODMAN & SHURTLEFF, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100087527-A1 | Curcumin Derivatives | CODMAN & SHURTLEFF, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374960-A1 | Method of Topically Administering a Curcumin Derivative | S100A11, S100A4, S100A6 | LCK 2467/4885ALOX12 100/4885ALOX5 37/4885 |
| US-20130150628-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE | CPT1A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCB1 | LCK 4307/4885ALOX12 378/4885ALOX5 296/4885 |
| US-20140163116-A1 | METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE | HDAC5, HDAC6, CPT1A | LCK 3096/4885ALOX12 98/4885ALOX5 44/4885 |
| US-20170224637-A1 | INTRANSAL DELIVERY OF CURCUMIN | FABP7, FABP2, NDUFB5 | LCK 4207/4885ALOX12 323/4885ALOX5 581/4885 |
| US-20100087527-A1 | Curcumin Derivatives | CPT1A, S100A10, PKD1 | LCK 4234/4885ALOX12 209/4885ALOX5 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.